Many patients with cancer experience moderate or severe pain requiring treatment with strong opioids. However, not all opioids are well tolerated by all patients. This JAMA Clinical Evidence Synopsis summarizes a published Cochrane review 1 that examined the association of oxycodone (any formulation or route of administration) compared with placebo or an active drug (including alternative forms of oxycodone) for treating cancer pain in adults.
[95% CI, −0.04 to 0.32]; Figure) . The most commonly reported adverse events were constipation, drowsiness, and nausea in the studies comparing CR and IR oxycodone (for constipation, 13 . There were no or only minor differences in adverse event rates, treatment acceptability or quality-of-life ratings in studies comparing CR oxycodone with either IR oxycodone or CR morphine. The remaining studies reported different drug comparisons and found no consistent differences associated with oxycodone for treating pain intensity, adverse events, or treatment acceptability. The evidence was limited by the methodological quality and small size of the studies.
Discussion
Low-quality evidence shows that for adults with cancer pain, oxycodone is not associated with better pain relief or fewer adverse events compared with other strong opioids, including morphine or oxymorphone.
Limitations
The evidence quality was low due to small sample sizes in some cases and important study limitations in all cases, including heterogeneous definitions of cancer pain and high levels of attrition, with data missing from more than 20% of the patients for pain intensity and more than 15% of the patients for adverse events.
Comparison of Findings With Current Practice Guidelines
The National Institute for Health and Care Excellence recommends morphine as first-line opioid 2 because it is less expensive than other alternatives. The European Association of Palliative Care recommends that any oral opioid is appropriate for first-line use. 3 Our review found no differences in pain control between CR and IR oxycodone; however, CR opioids are generally recommended for maintenance of pain control compared with IR opioids, 2, 5, 6 and are CLINICAL QUESTION Is oxycodone associated with greater efficacy and fewer adverse events compared with alternative analgesics for cancer pain?
BOTTOM LINE Oxycodone was not associated with superior cancer pain relief or fewer adverse effects compared with other strong opioids, such as morphine or oxymorphone.
However, the quality of the evidence was low. Comparisons: Controlled-release (CR) oxycodone vs (1) immediate-release (IR) oxycodone (4 studies); (2) CR morphine (6 studies); (3) CR hydromorphone (1 study); (4) extended-release (ER) oxymorphone (1 study); (5) ER tapentadol (1 study); intravenous (IV) oxycodone vs rectal oxycodone (1 study); IV oxycodone followed by IR oxycodone vs IV morphine followed by IR morphine (1 study); intramuscular oxycodone vs oral oxycodone (1 study); intramuscular oxycodone vs intramuscular morphine vs intramuscular codeine (1 study) Source: Data were adapted with permission from Wiley. 1 CR indicates controlled release; ER, extended release; IR, immediate release. SMD was calculated using the inverse variance fixed-effect method. The SMD can be interpreted as an effect size, with small effect size values of 0.2; medium, 0.5; and large, 0.8. 4 The size of the data markers indicates the weight of the study. a IR oxycodone is input as the comparator group in this specific drug comparison grouping. b Week 4 data.
